PPAR agonists regulate brain gene expression: Relationship to their effects on ethanol consumption
| Autor: | Yuri A. Blednov, R. Adron Harris, Laura B. Ferguson, Dana Most |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Alkanesulfonates
Male medicine.medical_specialty Tesaglitazar Alcohol Drinking Peroxisome Proliferator-Activated Receptors Drinking Gene Expression Prefrontal Cortex Peroxisome proliferator-activated receptor Retinoid X receptor Biology Article PPAR agonist Cellular and Molecular Neuroscience chemistry.chemical_compound Fenofibrate Internal medicine medicine Animals Receptor Pharmacology chemistry.chemical_classification Bezafibrate Ethanol Phenylpropionates Drinking Water Central Nervous System Depressants Taste Perception Amygdala Mice Inbred C57BL Endocrinology Liver chemistry Nuclear receptor Central Nervous System Agents medicine.drug |
| Zdroj: | Neuropharmacology. 86:397-407 |
| ISSN: | 0028-3908 |
| DOI: | 10.1016/j.neuropharm.2014.06.024 |
| Popis: | Peroxisome proliferator-activated receptors (PPARs) are nuclear hormone receptors that act as ligand-activated transcription factors. Although prescribed for dyslipidemia and type-II diabetes, PPAR agonists also possess anti-addictive characteristics. PPAR agonists decrease ethanol consumption and reduce withdrawal severity and susceptibility to stress-induced relapse in rodents. However, the cellular and molecular mechanisms facilitating these properties have yet to be investigated. We tested three PPAR agonists in a continuous access two-bottle choice (2BC) drinking paradigm and found that tesaglitazar (PPARα/γ; 1.5 mg/kg) and fenofibrate (PPARα; 150 mg/kg) decreased ethanol consumption in male C57BL/6J mice while bezafibrate (PPARα/γ/β; 75 mg/kg) did not. We hypothesized that changes in brain gene expression following fenofibrate and tesaglitazar treatment lead to reduced ethanol drinking. We studied unbiased genomic profiles in areas of the brain known to be important for ethanol dependence, the prefrontal cortex (PFC) and amygdala, and also profiled gene expression in liver. Genomic profiles from the non-effective bezafibrate treatment were used to filter out genes not associated with ethanol consumption. Because PPAR agonists are anti-inflammatory, they would be expected to target microglia and astrocytes. Surprisingly, PPAR agonists produced a strong neuronal signature in mouse brain, and fenofibrate and tesaglitazar (but not bezafibrate) targeted a subset of GABAergic interneurons in the amygdala. Weighted gene co-expression network analysis (WGCNA) revealed co-expression of treatment-significant genes. Functional annotation of these gene networks suggested that PPAR agonists might act via neuropeptide and dopaminergic signaling pathways in the amygdala. Our results reveal gene targets through which PPAR agonists can affect alcohol consumption behavior. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect